Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Protalix Biotherapeutics Inc V.PLX.H


Primary Symbol: PLX

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.


NYSEAM:PLX - Post by User

Comment by ohbehaveon Jun 18, 2019 8:34pm
66 Views
Post# 29838156

RE:Very illiquid

RE:Very illiquidIt's painful to watch any stock drop on low volumes but weak hands selling a few shares in a poor market and tanking the share price doesnt reflect the value/potential of any company. Beyond staying healthy while adding production/cash flow the most difficult challenge for management these days is to create interest in the story but as seen on June 7th even a small amount of buy side demand can move the stock up just as quickly. The question is when will interest return to this sector acknowledging that $ typically moves to the Junior sector last. That said, including todays PLX PR and the Transmountain pipeline announcement we've had a few positives in the last few months so if they can keep the operations on track with the next two wells and we get the right outcome in October the stock trajectory should take care of itself ... GLTA      
<< Previous
Bullboard Posts
Next >>